Search

Your search keyword '"Uchikawa, Shinsuke"' showing total 280 results
Start Over Author "Uchikawa, Shinsuke"
280 results on '"Uchikawa, Shinsuke"'

1. Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure

Author

Murakami, Serami, Imamura, Michio, Uchida, Takuro, Suehiro, Yosuke, Namba, Maiko, Fujii, Yasutoshi, Uchikawa, Shinsuke, Teraoka, Yuji, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Kawaoka, Tomokazu, Miki, Daiki, Hayes, Nelson C., Tsuge, Masataka, Aikata, Hiroshi, Ohira, Masahiro, Ohdan, Hideki, and Oka, Shiro

Published
2023
Full Text
View/download PDF

3. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma

Author

Yamauchi, Masami, Ono, Atsushi, Amioka, Kei, Fujii, Yasutoshi, Nakahara, Hikaru, Teraoka, Yuji, Uchikawa, Shinsuke, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Miki, Daiki, Kawaoka, Tomokazu, Tsuge, Masataka, Imamura, Michio, Hayes, C. Nelson, Ohishi, Waka, Kishi, Takeshi, Kimura, Mizuki, Suzuki, Natsumi, Arihiro, Koji, Aikata, Hiroshi, Chayama, Kazuaki, and Oka, Shiro

Published
2023
Full Text
View/download PDF

4. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study

Author

Johira, Yusuke, Nakahara, Takashi, Kinami, Takahiro, Yamasaki, Shintaro, Kosaka, Masanari, Shirane, Yuki, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Kodama, Kenichiro, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Kawaoka, Tomokazu, Hayes, C. Nelson, Tsuge, Masataka, Imamura, Michio, Aikata, Hiroshi, and Oka, Shiro

Published
2023
Full Text
View/download PDF

6. Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection

Author

Kodama, Kenichiro, Kawaoka, Tomokazu, Kosaka, Masanari, Johira, Yusuke, Shirane, Yuki, Miura, Ryoichi, Yano, Shigeki, Murakami, Serami, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Uchikawa, Shinsuke, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Miki, Daiki, Imamura, Michio, Kuroda, Shintaro, Kobayashi, Tsuyoshi, Ohdan, Hideki, Aikata, Hiroshi, and Chayama, Kazuaki

Published
2022
Full Text
View/download PDF

8. Useful Predictor for Exacerbation of Esophagogastric Varices after Hepatitis C Virus Eradication by Direct-Acting Antivirals

Author

Nagaoki, Yuko, primary, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Kawaoka, Tomokazu, additional, Miki, Daiki, additional, Aikata, Hiroshi, additional, Hayes, C. Nelson, additional, Tsuge, Masataka, additional, and Oka, Shiro, additional

Published
2024
Full Text
View/download PDF

9. Influence of dispersion slope on the diagnosis of liver fibrosis by the shear wave in metabolic dysfunction‐associated steatotic liver disease

Author

Ueda, Naoyuki, primary, Mokuda, Sho, additional, Kawaoka, Tomokazu, additional, Uchikawa, Shinsuke, additional, Amioka, Kei, additional, Tsuge, Masataka, additional, Asada, Kana, additional, Okada, Yuri, additional, Kobayashi, Yui, additional, Ishikawa, Mai, additional, Arase, Takashi, additional, Arihiro, Koji, additional, and Oka, Shiro, additional

Published
2024
Full Text
View/download PDF

10. Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study

Author

Naruto, Kensuke, Kawaoka, Tomokazu, Kodama, Kenichiro, Ogawa, Yutaro, Amioka, Kei, Yoshikawa, Yuki, Kikukawa, Chihiro, Suehiro, Yousuke, Yamaoka, Kenji, Ando, Yuwa, Kosaka, Yumi, Uchikawa, Shinsuke, Nakahara, Takashi, Murakami, Eisuke, Ono, Atsushi, Uchida, Takuro, Yamauchi, Masami, Okamoto, Wataru, Takahashi, Shoichi, Imamura, Michio, Chosa, Keigo, Awai, Kazuo, Kubo, Katsumaro, Nagata, Yasushi, Chayama, Kazuaki, and Aikata, Hiroshi

Published
2022
Full Text
View/download PDF

11. Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices

Author

Shirane, Yuki, Murakami, Eisuke, Imamura, Michio, Kosaka, Masanari, Johira, Yusuke, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Uchikawa, Shinsuke, Teraoka, Yuji, Uchida, Takuro, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Kawaoka, Tomokazu, Miki, Daiki, Yamauchi, Masami, Okamoto, Wataru, Tsuge, Masataka, Chosa, Keigo, Awai, Kazuo, Aikata, Hiroshi, and Oka, Shiro

Published
2022
Full Text
View/download PDF

12. Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma.

Author

Uchikawa, Shinsuke, Kawaoka, Tomokazu, Murakami, Serami, Miura, Ryoichi, Shirane, Yuki, Johira, Yusuke, Kosaka, Masanari, Fujii, Yasutoshi, Fujino, Hatsue, Ono, Atsushi, Murakami, Eisuke, Miki, Daiki, Hayes, C. Nelson, Tsuge, Masataka, and Oka, Shiro

Subjects
*TUMOR markers, *IMMUNE checkpoint inhibitors, *BIOMARKERS, *HEPATOCELLULAR carcinoma, *DISEASE progression
Abstract

Aim Methods Results Conclusions When evaluating response to immune checkpoint inhibitor therapy, the tumor sometimes initially swells before shrinking and ultimately responding, also called pseudo‐progression. In this study, we analyzed whether tumor markers were useful for reflecting the treatment response.Thirty‐three patients who were treated with durvalumab plus tremelimumab combination therapy (Dur + Tre) were enrolled. Their functional reserve was Child–Pugh grade A. Their tumor markers α‐fetoprotein (AFP), des‐γ‐carboxy prothrombin (DCP), or AFP‐Lectin 3 fraction (AFP‐L3) were positive. Tumor markers were evaluated before treatment and at 1, 4, and 8 weeks after the start of treatment. The first radiological evaluation was carried out at 4 weeks and the second evaluation at 8–12 weeks. The responders included those with complete response and partial response and the nonresponders included those with stable disease (SD) and progression disease at best response evaluated by Response Evaluation Criteria in Solid Tumors.In the responder group, the change ratio of AFP, DCP, and AFP‐L3 specifically decreased at 8 weeks. In the nonresponder group, the change ratio of DCP specifically increased at 4 weeks. The optimal cut‐off value to divide responders and nonresponders at 4 weeks was approximately −40%. The ratio of responders was 72.7% in the patients whose AFP or DCP decreased over 40% at 4 weeks.The change in tumor markers is a more useful predicter of tumor response to Dur + Tre than imaging evaluation alone. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Correction to: Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure

Author

Murakami, Serami, Imamura, Michio, Uchida, Takuro, Suehiro, Yosuke, Namba, Maiko, Fujii, Yasutoshi, Uchikawa, Shinsuke, Teraoka, Yuji, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Kawaoka, Tomokazu, Miki, Daiki, Hayes, Nelson C., Tsuge, Masataka, Aikata, Hiroshi, Ohira, Masahiro, Ohdan, Hideki, and Oka, Shiro

Published
2023
Full Text
View/download PDF

15. Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma

Author

Shirane, Yuki, primary, Fujii, Yasutoshi, additional, Ono, Atsushi, additional, Nakahara, Hikaru, additional, Hayes, Clair Nelson, additional, Miura, Ryoichi, additional, Murakami, Serami, additional, Sakamoto, Naoya, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Miki, Daiki, additional, Kawaoka, Tomokazu, additional, Arihiro, Koji, additional, Tsuge, Masataka, additional, and Oka, Shiro, additional

Published
2024
Full Text
View/download PDF

16. Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs

Author

Hiyama, Yuichi, primary, Fujino, Hatsue, additional, Namba, Maiko, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Kawaoka, Tomokazu, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, and Oka, Shiro, additional

Published
2024
Full Text
View/download PDF

17. Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma

Author

Kinami, Takahiro, primary, Uchikawa, Shinsuke, additional, Kawaoka, Tomokazu, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, and Oka, Shiro, additional

Published
2024
Full Text
View/download PDF

18. Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Author

Yano, Shigeki, primary, Kawaoka, Tomokazu, additional, Yamasaki, Shintaro, additional, Johira, Yusuke, additional, Kosaka, Masanari, additional, Shirane, Yuki, additional, Miura, Ryoichi, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, Teraoka, Yuji, additional, Kouno, Hirotaka, additional, Takaki, Shintaro, additional, Mori, Nami, additional, Tsuji, Keiji, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

20. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk

Author

Kosaka, Yumi, Kawaoka, Tomokazu, Aikata, Hiroshi, Suehiro, Yosuke, Yamaoka, Kenji, Ando, Yuwa, Namba, Maiko, Takeuchi, Yasue, Fujii, Yasutomo, Uchikawa, Shinsuke, Kodama, Kenichiro, Oya, Kazuki, Morio, Kei, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Yamauchi, Masami, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Baba, Yasutaka, Awai, Kazuo, Kimura, Tomoki, Nagata, Yasushi, and Chayama, Kazuaki

Published
2020
Full Text
View/download PDF

21. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study

Author

Nagaoki, Yuko, Hyogo, Hideyuki, Ando, Yuwa, Kosaka, Yumi, Uchikawa, Shinsuke, Nishida, Yuno, Teraoka, Yuji, Morio, Kei, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Yamauchi, Masami, Okamoto, Wataru, Kawaoka, Tomokazu, Tsuge, Masataka, Hiramatsu, Akira, Miki, Daiki, Imamura, Michio, Takahashi, Shoichi, Chayama, Kazuaki, and Aikata, Hiroshi

Published
2021
Full Text
View/download PDF

24. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab

Author

Yano, Shigeki, Kawaoka, Tomokazu, Johira, Yusuke, Miura, Ryoichi, Kosaka, Masanari, Shirane, Yuki, Murakami, Serami, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Yamaoka, Kenji, Kodama, Kenichiro, Uchikawa, Shinsuke, Fujino, Hatsue, Ohno, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Imamura, Michio, Mori, Keiichi, Arihiro, Kouji, Kuroda, Shintaro, Kobayashi, Tsuyoshi, Ohdan, Hideki, and Aikata, Hiroshi

Published
2021
Full Text
View/download PDF

25. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.

Author

Kikugawa, Chihiro, Uchikawa, Shinsuke, Kawaoka, Tomokazu, Kinami, Takahiro, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Yamaoka, Kenji, Tsuge, Masataka, Kosaka, Yumi, Ohya, Kazuki, Mori, Nami, Takaki, Shintaro, Tsuji, Keiji, Kouno, Hirotaka, Kohno, Hiroshi, Morio, Kei, Moriya, Takashi, and Nonaka, Michihiro

Subjects
*LIVER physiology, *THERAPEUTIC use of antineoplastic agents, *COMBINATION drug therapy, *PEARSON correlation (Statistics), *STATISTICAL significance, *BEVACIZUMAB, *FISHER exact test, *LOGISTIC regression analysis, *SORAFENIB, *TREATMENT effectiveness, *RETROSPECTIVE studies, *MANN Whitney U Test, *CHI-squared test, *MULTIVARIATE analysis, *DESCRIPTIVE statistics, *IMMUNE checkpoint inhibitors, *LONGITUDINAL method, *KAPLAN-Meier estimator, *LOG-rank test, *LUNG tumors, *STATISTICS, *CANCER patient psychology, *PROGRESSION-free survival, *DATA analysis software, *HEPATOCELLULAR carcinoma, *LIVER function tests, *OVERALL survival, *PROPORTIONAL hazards models
Abstract

Introduction: Systemic therapy is recommended for patients with Child-Pugh A in hepatocellular carcinoma (HCC). We analyzed the outcomes of a cohort of patients with HCC who received either sorafenib (Sor), lenvatinib (Len) or atezolizumab plus bevacizumab (Atezo + Bev) as first-line systemic therapy for HCC, with the aim of identifying prognostic factors for survival. Methods: A total of 825 patients with advanced HCC and Child-Pugh A or B received either Sor, Len or Atezo + Bev as first-line systemic therapy. Liver function was assessed according to the Child-Pugh score and the modified albumin-bilirubin (mALBI) grade. Results: Prognosis was analyzed according to liver function such as Child-Pugh classifications, scores, and mALBI grades that worsened with a decline in liver function (p <0.001 for all). A Child-Pugh score of 7 was a factor significantly associated with OS. In patients with a Child-Pugh score of 7, an mALBI grade of 3 was an independent predictor of OS. In Child-Pugh B patients with HCC, receiving Atezo + Bev was identified as a factor associated with PFS. Conclusion: Determining the hepatic reserve of patients with unresectable HCC might be useful for identifying patents suitable for systemic treatment for HCC. Atezo + Bev might prolong the PFS of patients with a Child-Pugh score of 7. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Outcomes of patients with Child-Pugh B and unresectable hepatocellular carcinoma undergoing first-line systemic treatment with sorafenib, lenvatinib, or atezolizumab plus bevacizumab

Author

Kikugawa, Chihiro, primary, Uchikawa, Shinsuke, additional, Kawaoka, Tomokazu, additional, Kinami, Takahiro, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Tsuge, Masataka, additional, Kosaka, Yumi, additional, Ohya, Kazuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Kouno, Hirotaka, additional, Kohno, Hiroshi, additional, Morio, Kei, additional, Moriya, Takashi, additional, Nonaka, Michihiro, additional, Aisaka, Yasuyuki, additional, Masaki, Keiichi, additional, Honda, Yohji, additional, Naeshiro, Noriaki, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

27. Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment

Author

Tamura, Yosuke, primary, Ono, Atsushi, additional, Nakahara, Hikaru, additional, Hayes, Clair Nelson, additional, Fujii, Yasutoshi, additional, Zhang, Peiyi, additional, Yamauchi, Masami, additional, Uchikawa, Shinsuke, additional, Teraoka, Yuji, additional, Uchida, Takuro, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Tsuge, Masataka, additional, Serikawa, Masahiro, additional, Miki, Daiki, additional, Kawaoka, Tomokazu, additional, Okamoto, Wataru, additional, Imamura, Michio, additional, Nakamura, Yuko, additional, Awai, Kazuo, additional, Kobayashi, Tsuyoshi, additional, Ohdan, Hideki, additional, Fujita, Masashi, additional, Nakagawa, Hidewaki, additional, Chayama, Kazuaki, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

28. Correlation between serum pro‐inflammatory cytokine levels and the prognosis of the patients with acute liver failure

Author

Murakami, Serami, primary, Uchida, Takuro, additional, Imamura, Michio, additional, Suehiro, Yosuke, additional, Namba, Maiko, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Teraoka, Yuji, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Kawaoka, Tomokazu, additional, Miki, Daiki, additional, Hayes, C Nelson, additional, Tsuge, Masataka, additional, Ohira, Masahiro, additional, Ohdan, Hideki, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

29. The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib

Author

Chihiro, Kikukawa, primary, Kawaoka, Tomokazu, additional, Uchikawa, Shinsuke, additional, Kinami, Takahiro, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Teraoka, Yuji, additional, Uchida, Takuro, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

30. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt

Author

Namba, Maiko, Kawaoka, Tomokazu, Aikata, Hiroshi, Kodama, Kenichiro, Uchikawa, Shinsuke, Ohya, Kazuki, Morio, Kei, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Yamauchi, Masami, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Baba, Yasutaka, Awai, Kazuo, and Chayama, Kazuaki

Published
2019
Full Text
View/download PDF

31. Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma

Author

Kosaka, Yumi, primary, Kawaoka, Tomokazu, additional, Kosaka, Masanari, additional, Shirane, Yuki, additional, Miura, Ryoichi, additional, Murakami, Serami, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Kodama, Kenichiro, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ohno, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Imamura, Michio, additional, and Aikata, Hiroshi, additional

Published
2023
Full Text
View/download PDF

32. Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein

Author

Kinami, Takahiro, primary, Amioka, Kei, additional, Kawaoka, Tomokazu, additional, Uchikawa, Shinsuke, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

33. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

Author

Yamauchi, Masami, Ono, Atsushi, Ishikawa, Akira, Kodama, Kenichiro, Uchikawa, Shinsuke, Hatooka, Haruna, Zhang, Peiyi, Teraoka, Yuji, Morio, Kei, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Miki, Daiki, Kawaoka, Tomokazu, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Hayes, Clair Nelson, Fujita, Masashi, Nakagawa, Hidewaki, Yasui, Wataru, Aikata, Hiroshi, and Chayama, Kazuaki

Published
2020
Full Text
View/download PDF

34. Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy

Author

Saeki, Issei, primary, Yamasaki, Takahiro, additional, Yamauchi, Yurika, additional, Kawaoka, Tomokazu, additional, Uchikawa, Shinsuke, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, Kobayashi, Kazufumi, additional, Kondo, Takayuki, additional, Ogasawara, Sadahisa, additional, Chiba, Tetsuhiro, additional, Kawano, Reo, additional, Chayama, Kazuaki, additional, Kato, Naoya, additional, and Takami, Taro, additional

Published
2023
Full Text
View/download PDF

35. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma

Author

Yamauchi, Masami, primary, Ono, Atsushi, additional, Amioka, Kei, additional, Fujii, Yasutoshi, additional, Nakahara, Hikaru, additional, Teraoka, Yuji, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Miki, Daiki, additional, Kawaoka, Tomokazu, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Hayes, Nelson, additional, Ohishi, Waka, additional, Kishi, Takeshi, additional, Kimura, Mizuki, additional, Suzuki, Natsumi, additional, Arihiro, Koji, additional, Aikata, Hiroshi, additional, Chayama, Kazuaki, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

36. Caroli's disease in two siblings

Author

Johira, Yusuke, primary, Kawaoka, Tomokazu, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

37. Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma—Consideration of the Locations of Target Lesions

Author

Yano, Shigeki, primary, Kimura, Tomoki, additional, Kawaoka, Tomokazu, additional, Kinami, Takahiro, additional, Yamasaki, Shintaro, additional, Johira, Yusuke, additional, Kosaka, Masanari, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Imamura, Michio, additional, Hirokawa, Junichi, additional, Nagata, Yasushi, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

38. Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial

Author

Naruto, Kensuke, primary, Kawaoka, Tomokazu, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Shirane, Yuki, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Ogawa, Yutaro, additional, Yoshikawa, Yuki, additional, Yamaoka, Kenji, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Fujii, Yasutomo, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

39. Additional file 1 of Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices

Author

Shirane, Yuki, Murakami, Eisuke, Imamura, Michio, Kosaka, Masanari, Johira, Yusuke, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Uchikawa, Shinsuke, Teraoka, Yuji, Uchida, Takuro, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Kawaoka, Tomokazu, Miki, Daiki, Yamauchi, Masami, Okamoto, Wataru, Tsuge, Masataka, Chosa, Keigo, Awai, Kazuo, Aikata, Hiroshi, and Oka, Shiro

Abstract

Additional file 1. Supplementary figure 1. (a) Receiver operating characteristic (ROC) curve of hepatic venous pressure gradient (HVPG) measured after performing balloon-occluded retrograde transvenous obliteration (BRTO) (post-HVPG) and exacerbation of esophageal varices (EVs) after BRTO. (b) ROC curve of liver stiffness measurement (LSM) and prognosis after BRTO.

Published
2023
Full Text
View/download PDF

41. Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.

Author

Ando, Yuwa, primary, Kawaoka, Tomokazu, additional, Kosaka, Masanari, additional, Shirane, Yuki, additional, Johira, Yusuke, additional, Miura, Ryoichi, additional, Murakami, Serami, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Kosaka, Yumi, additional, Uchikawa, Shinsuke, additional, Kodama, Kenichiro, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Okamoto, Wataru, additional, Takahashi, Shoichi, additional, Imamura, Michio, additional, and Aikata, Hiroshi, additional

Published
2022
Full Text
View/download PDF

42. Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure

Author

Murakami, Serami, primary, Imamura, Michio, additional, Uchida, Takuro, additional, Suehiro, Yosuke, additional, Namba, Maiko, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Teraoka, Yuji, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Kawaoka, Tomokazu, additional, Miki, Daiki, additional, Hayes, C. Nelson, additional, Tsuge, Masataka, additional, Aikata, Hiroshi, additional, Ohira, Masahiro, additional, Ohdan, Hideki, additional, and Oka, Shiro, additional

Published
2022
Full Text
View/download PDF

43. Effect of supplemental branched-chain amino acid-enriched nutrients during endoscopic injection sclerotherapy or endoscopic variceal ligation in patients with liver cirrhosis

Author

Kikugawa, Chihiro, primary, Hiramatsu, Akira, additional, Kinami, Takahiro, additional, Yamasaki, Shintaro, additional, Johira, Yusuke, additional, Kosaka, Masanari, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Oono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Kawaoka, Tomokazu, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2022
Full Text
View/download PDF

44. Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma

Author

Amioka, Kei, primary, Kawaoka, Tomokazu, additional, Kinami, Takahiro, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Ono, Atsushi, additional, Yamauchi, Masami, additional, Imamura, Michio, additional, Kosaka, Yumi, additional, Ohya, Kazuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Masaki, Keiichi, additional, Honda, Yoji, additional, Kouno, Hirotaka, additional, Kohno, Hioshi, additional, Morio, Kei, additional, Moriya, Takashi, additional, Naeshiro, Noriaki, additional, Nonaka, Michihiro, additional, Aisaka, Yasuyuki, additional, Azakami, Takahiro, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2022
Full Text
View/download PDF

46. Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiff measurement predict the prognosis of the patients with gastric varices

Author

Shirane, Yuki, primary, Murakami, Eisuke, additional, Imamura, Michio, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Miura, Ryoichi, additional, Murakami, Serami, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Uchikawa, Shinsuke, additional, Teraoka, Yuji, additional, Uchida, Takuro, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Kawaoka, Tomokazu, additional, Miki, Daiki, additional, Yamauchi, Masami, additional, Okamoto, Wataru, additional, Tsuge, Masataka, additional, Chosa, Keigo, additional, Awai, Kazuo, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2022
Full Text
View/download PDF

47. The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma

Author

Zhang, Peiyi, primary, Ono, Atsushi, additional, Fujii, Yasutoshi, additional, Hayes, Clair Nelson, additional, Tamura, Yosuke, additional, Miura, Ryoichi, additional, Shirane, Yuki, additional, Nakahara, Hikaru, additional, Yamauchi, Masami, additional, Uchikawa, Shinsuke, additional, Uchida, Takuro, additional, Teraoka, Yuji, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Miki, Daiki, additional, Kawaoka, Tomokazu, additional, Okamoto, Wataru, additional, Makokha, Grace Naswa, additional, Imamura, Michio, additional, Arihiro, Koji, additional, Kobayashi, Tsuyoshi, additional, Ohdan, Hideki, additional, Fujita, Masashi, additional, Nakagawa, Hidewaki, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2022
Full Text
View/download PDF

48. Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.

Author

Ando, Yuwa, Kawaoka, Tomokazu, Kosaka, Masanari, Shirane, Yuki, Johira, Yusuke, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Kosaka, Yumi, Uchikawa, Shinsuke, Kodama, Kenichiro, Fujino, Hatsue, Nakahara, Takashi, Ono, Atushi, Murakami, Eisuke, Yamauchi, Masami, Okamoto, Wataru, and Takahashi, Shoichi

Subjects
ATEZOLIZUMAB, PROTEINURIA, BEVACIZUMAB, SYSTOLIC blood pressure, SERUM albumin
Abstract

Introduction: Proteinuria is one of the adverse events of atezolizumab plus bevacizumab combination therapy (Atezo + Bev) and can cause interruption in the use of Bev. However, the risk factors for proteinuria in patients with hepatocellular carcinoma (HCC) who are receiving Atezo + Bev have not yet been investigated. The aim of this study was to identify the risk factors for early onset of proteinuria in Atezo + Bev for patients with unresectable HCC. Methods: Sixty-four patients with Child-Pugh scores of 5–7, an Eastern Cooperative Oncology Group performance status of 0 or 1, and low level of proteinuria (1+ or less on a dipstick test and urine protein-to-creatinine ratio (UPCR) less than 2.0 g/g Cr) at the initiation of therapy were analyzed. The level of proteinuria was evaluated based on the Common Terminology Criteria for Adverse Events version 5.0. We adopted the UPCR for the quantitative test instead of a 24-h urine collection. The incidence of proteinuria and changes in liver function were retrospectively investigated. Results: The cumulative incidence of proteinuria over a 24-week period was 34.4%. Multivariate analysis showed that a low estimated glomerular filtration rate (hazard ratio [HR], 3.807; 95% confidence interval [CI], 1.579–9.180; p = 0.003), treatment for hypertension (HR, 6.224; 95% CI, 1.614–24.010; p = 0.008), and high systolic blood pressure (SBP) (HR, 2.649; 95% CI, 1.133–6.194; p = 0.025) were risk factors for proteinuria. Serum albumin levels and albumin-bilirubin scores in patients with proteinuria worsened. In addition, a mean SBP ≥135 mm Hg during treatment was the only risk factor for the development of severe proteinuria (UPCR >2 g/g Cr). Conclusion: Our study found that controlling blood pressure is extremely important for the management of proteinuria in patients with HCC who are receiving Atezo + Bev. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. A patient with polycystic liver disease combined with portal hypertension that died due to bacterial peritonitis as a secondary cause of death

Author

Miura, Ryoichi, primary, Imamura, Michio, additional, Amioka, Kei, additional, Kodama, Kenichiro, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ohno, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Kawaoka, Tomokazu, additional, Kido, Aya, additional, Sentani, Kazuhiro, additional, Oue, Naohide, additional, Arihiro, Koji, additional, and Aikata, Hiroshi, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results